Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain
Bruera, Eduardo ; Belzile, Michelle ; Neumann, Catherine M. ; Ford, I. ; Harsanyi, Zoltan ; Darke, Andrew
Springer
Published 1999
Springer
Published 1999
| ISSN: |
1433-7339
|
|---|---|
| Keywords: |
Key words Cancer ; Pain ; Morphine ; Suppositories ; Controlled release
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract We evaluated the safety and efficacy of controlled-release morphine sulphate suppositories administered 12-hourly and once daily in patients with chronic cancer in a randomized double-blind crossover trial. Pain was assessed using a 100-mm VAS pain scale and a five-point ordinal pain scale. The VAS pain intensity score was 17.5±17.2 after suppositories every 12 h, versus 16.2±13.4 after suppositories every 24 h (difference not significant). The difference between the mean VAS pain scores with 12-hourly and once-daily dosing was 1.3 mm (not significant). The mean ordinal pain scores were 1.0±0.7 versus 1.0±0.6 for 12-hourly and once-a-day dosing, respectively (not significant). A retrospective power analysis indicated that a difference of 5.9 mm was detectable, even with only 6 patients. Adverse events noted were constipation, nausea, anorexia, and dry mouth. The use of once-a-day controlled-release morphine suppository is a more convenient and equally effective alternative to twice a day dosing.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798296042242834433 |
|---|---|
| autor | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew |
| autorsonst | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew |
| book_url | http://dx.doi.org/10.1007/s005200050261 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM206017995 |
| issn | 1433-7339 |
| journal_name | Supportive care in cancer |
| materialart | 1 |
| notes | Abstract We evaluated the safety and efficacy of controlled-release morphine sulphate suppositories administered 12-hourly and once daily in patients with chronic cancer in a randomized double-blind crossover trial. Pain was assessed using a 100-mm VAS pain scale and a five-point ordinal pain scale. The VAS pain intensity score was 17.5±17.2 after suppositories every 12 h, versus 16.2±13.4 after suppositories every 24 h (difference not significant). The difference between the mean VAS pain scores with 12-hourly and once-daily dosing was 1.3 mm (not significant). The mean ordinal pain scores were 1.0±0.7 versus 1.0±0.6 for 12-hourly and once-a-day dosing, respectively (not significant). A retrospective power analysis indicated that a difference of 5.9 mm was detectable, even with only 6 patients. Adverse events noted were constipation, nausea, anorexia, and dry mouth. The use of once-a-day controlled-release morphine suppository is a more convenient and equally effective alternative to twice a day dosing. |
| package_name | Springer |
| publikationsjahr_anzeige | 1999 |
| publikationsjahr_facette | 1999 |
| publikationsjahr_intervall | 8004:1995-1999 |
| publikationsjahr_sort | 1999 |
| publisher | Springer |
| reference | 7 (1999), S. 280-283 |
| schlagwort | Key words Cancer Pain Morphine Suppositories Controlled release |
| search_space | articles |
| shingle_author_1 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew |
| shingle_author_2 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew |
| shingle_author_3 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew |
| shingle_author_4 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew |
| shingle_catch_all_1 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain Key words Cancer Pain Morphine Suppositories Controlled release Key words Cancer Pain Morphine Suppositories Controlled release Abstract We evaluated the safety and efficacy of controlled-release morphine sulphate suppositories administered 12-hourly and once daily in patients with chronic cancer in a randomized double-blind crossover trial. Pain was assessed using a 100-mm VAS pain scale and a five-point ordinal pain scale. The VAS pain intensity score was 17.5±17.2 after suppositories every 12 h, versus 16.2±13.4 after suppositories every 24 h (difference not significant). The difference between the mean VAS pain scores with 12-hourly and once-daily dosing was 1.3 mm (not significant). The mean ordinal pain scores were 1.0±0.7 versus 1.0±0.6 for 12-hourly and once-a-day dosing, respectively (not significant). A retrospective power analysis indicated that a difference of 5.9 mm was detectable, even with only 6 patients. Adverse events noted were constipation, nausea, anorexia, and dry mouth. The use of once-a-day controlled-release morphine suppository is a more convenient and equally effective alternative to twice a day dosing. 1433-7339 14337339 Springer |
| shingle_catch_all_2 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain Key words Cancer Pain Morphine Suppositories Controlled release Key words Cancer Pain Morphine Suppositories Controlled release Abstract We evaluated the safety and efficacy of controlled-release morphine sulphate suppositories administered 12-hourly and once daily in patients with chronic cancer in a randomized double-blind crossover trial. Pain was assessed using a 100-mm VAS pain scale and a five-point ordinal pain scale. The VAS pain intensity score was 17.5±17.2 after suppositories every 12 h, versus 16.2±13.4 after suppositories every 24 h (difference not significant). The difference between the mean VAS pain scores with 12-hourly and once-daily dosing was 1.3 mm (not significant). The mean ordinal pain scores were 1.0±0.7 versus 1.0±0.6 for 12-hourly and once-a-day dosing, respectively (not significant). A retrospective power analysis indicated that a difference of 5.9 mm was detectable, even with only 6 patients. Adverse events noted were constipation, nausea, anorexia, and dry mouth. The use of once-a-day controlled-release morphine suppository is a more convenient and equally effective alternative to twice a day dosing. 1433-7339 14337339 Springer |
| shingle_catch_all_3 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain Key words Cancer Pain Morphine Suppositories Controlled release Key words Cancer Pain Morphine Suppositories Controlled release Abstract We evaluated the safety and efficacy of controlled-release morphine sulphate suppositories administered 12-hourly and once daily in patients with chronic cancer in a randomized double-blind crossover trial. Pain was assessed using a 100-mm VAS pain scale and a five-point ordinal pain scale. The VAS pain intensity score was 17.5±17.2 after suppositories every 12 h, versus 16.2±13.4 after suppositories every 24 h (difference not significant). The difference between the mean VAS pain scores with 12-hourly and once-daily dosing was 1.3 mm (not significant). The mean ordinal pain scores were 1.0±0.7 versus 1.0±0.6 for 12-hourly and once-a-day dosing, respectively (not significant). A retrospective power analysis indicated that a difference of 5.9 mm was detectable, even with only 6 patients. Adverse events noted were constipation, nausea, anorexia, and dry mouth. The use of once-a-day controlled-release morphine suppository is a more convenient and equally effective alternative to twice a day dosing. 1433-7339 14337339 Springer |
| shingle_catch_all_4 | Bruera, Eduardo Belzile, Michelle Neumann, Catherine M. Ford, I. Harsanyi, Zoltan Darke, Andrew Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain Key words Cancer Pain Morphine Suppositories Controlled release Key words Cancer Pain Morphine Suppositories Controlled release Abstract We evaluated the safety and efficacy of controlled-release morphine sulphate suppositories administered 12-hourly and once daily in patients with chronic cancer in a randomized double-blind crossover trial. Pain was assessed using a 100-mm VAS pain scale and a five-point ordinal pain scale. The VAS pain intensity score was 17.5±17.2 after suppositories every 12 h, versus 16.2±13.4 after suppositories every 24 h (difference not significant). The difference between the mean VAS pain scores with 12-hourly and once-daily dosing was 1.3 mm (not significant). The mean ordinal pain scores were 1.0±0.7 versus 1.0±0.6 for 12-hourly and once-a-day dosing, respectively (not significant). A retrospective power analysis indicated that a difference of 5.9 mm was detectable, even with only 6 patients. Adverse events noted were constipation, nausea, anorexia, and dry mouth. The use of once-a-day controlled-release morphine suppository is a more convenient and equally effective alternative to twice a day dosing. 1433-7339 14337339 Springer |
| shingle_title_1 | Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain |
| shingle_title_2 | Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain |
| shingle_title_3 | Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain |
| shingle_title_4 | Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:45:48.298Z |
| titel | Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain |
| titel_suche | Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM206017995 |